Key result
Once-daily diltiazem SR reduces weekly angina episodes by ~68% versus placebo.
Why the study?
The efficacy of once daily sustained-release diltiazem at two dose levels in stable angina patients with positive exercise test was assessed to determine its prophylactic benefit.
Does once daily sustained-release diltiazem reduce angina episodes and improve exercise tolerance in patients with stable angina?
RCT (n=182)
Does once daily sustained-release diltiazem reduce angina episodes and improve exercise tolerance in patients with stable angina?
Once daily sustained-release diltiazem (200 mg and 300 mg) effectively reduces angina episodes and improves exercise tolerance in patients with stable angina.
Answers are grounded in this paper and cite their sources.
Supports once-daily SR diltiazem for stable angina symptom control; extends evidence for sustained-release calcium-channel blockade.
This placebo-controlled study assessed once daily sustained-release (SR) diltiazem, 200 and 300 mg, in 182 stable angina patients with positive exercise test. 2. Exercise testing was performed at baseline after a 7 day placebo run-in period, and repeated after 7 days of treatment, 25.0 +/- 0.1 h postdose. 3. Diltiazem (200 and 300 mg) produced respectively a 68% and a 64% decrease in weekly angina episodes, and placebo a 15% decrease (P < 0.05). Similarly, both dose levels produced a 70% decrease in nitroglycerin consumption, whereas no difference was obtained with placebo (P < 0.01). The increase in time to ischaemic threshold was significantly superior for 200 mg and 300 mg diltiazem when compared with placebo (75.2 and 91.5 s respectively vs 47.0 s) (P < 0.05); increase in time to anginal threshold was also significantly greater for diltiazem when compared with placebo (84.6 and 85.9 s respectively vs 43.9 s) (P < 0.05). 4. Only one patient experienced worsening of angina and had to be withdrawn from the study. 5. This study demonstrates 200 and 300 mg SR diltiazem is effective when given once-a-day in the prophylaxis of stable exertional angina. This once daily formulation should improve patients' compliance and comfort.
No takes yet. Share an insight, caveat, or question.
Francès et al. (1995) conducted an RCT in Stable angina (n=182). Sustained-release diltiazem vs. Placebo was evaluated on Decrease in weekly angina episodes (p=< 0.05). Once daily sustained-release diltiazem decreased weekly angina episodes by 68% and 64% respectively, compared to 15% with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: